The NTSR1 gene (Neurotensin Receptor 1) encodes a G protein-coupled receptor (GPCR) that binds the neuropeptide neurotensin (NT) with high affinity (Kd ~ 0.1 nM). NTSR1 is a Class A rhodopsin-like GPCR that couples primarily to Gq proteins, activating phospholipase C (PLC) and leading to protein kinase C (PKC) activation, calcium mobilization, and MAPK/ERK signaling pathway activation. In the brain, NTSR1 is highly expressed in regions rich in dopaminergic neurons, where it plays a critical role in modulating [dopamine signaling](/mechanisms/dopamine-signaling) andMotor control[@vincent1995][@stgelais2004].
The neurotensin system has been increasingly recognized for its involvement in neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease) (PD) where NTSR1 modulates dopaminergic neuron survival and function. Additionally, NTSR1 is implicated in [Alzheimer's disease](/diseases/alzheimers-disease) (AD), schizophrenia, and various cancers. The receptor represents a promising therapeutic target, with both agonists and antagonists under investigation for neurological disorders[@bjornstrom2018][@yang2020].
The NTSR1 gene (Neurotensin Receptor 1) encodes a G protein-coupled receptor (GPCR) that binds the neuropeptide neurotensin (NT) with high affinity (Kd ~ 0.1 nM). NTSR1 is a Class A rhodopsin-like GPCR that couples primarily to Gq proteins, activating phospholipase C (PLC) and leading to protein kinase C (PKC) activation, calcium mobilization, and MAPK/ERK signaling pathway activation. In the brain, NTSR1 is highly expressed in regions rich in dopaminergic neurons, where it plays a critical role in modulating [dopamine signaling](/mechanisms/dopamine-signaling) andMotor control[@vincent1995][@stgelais2004].
The neurotensin system has been increasingly recognized for its involvement in neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease) (PD) where NTSR1 modulates dopaminergic neuron survival and function. Additionally, NTSR1 is implicated in [Alzheimer's disease](/diseases/alzheimers-disease) (AD), schizophrenia, and various cancers. The receptor represents a promising therapeutic target, with both agonists and antagonists under investigation for neurological disorders[@bjornstrom2018][@yang2020].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Neurotensin Receptor 1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>NTSR1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Neurotensin Receptor 1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>2q24.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[4919](https://www.ncbi.nlm.nih.gov/gene/4919)</td></tr>
<tr><td><strong>OMIM</strong></td><td>162650</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000102468</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P21439](https://www.uniprot.org/uniprot/P21439)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease, Alzheimer's Disease, Schizophrenia, Cancer</td></tr>
</table>
</div>
The NTSR1 gene is located on chromosome 2q24.1 and spans approximately 30 kilobases. It consists of multiple exons that encode a GPCR protein of approximately 418 amino acids.
| Property | Value |
|----------|-------|
| Gene Symbol | NTSR1 |
| Chromosomal Location | 2q24.1 |
| NCBI Gene ID | 4919 |
| Ensembl ID | ENSG00000102468 |
| UniProt | P21439 |
| RefSeq | NM_002531 |
The NTSR1 protein contains the classic seven-transmembrane domain structure of Class A GPCRs:
Recent cryo-EM structures have revealed the detailed molecular interactions between NTSR1 and neurotensin, providing insights for rational drug design[@tang2022].
NTSR1 activation initiates multiple signaling cascades:
Gq-PLC Pathway:
MAPK/ERK Pathway:
Beyond Gq, NTSR1 can activate:
| Pathway | Mechanism | Cellular Effects |
|---------|-----------|------------------|
| PI3K/AKT | Gq-dependent and β-arrestin | Cell survival |
| JNK | Gq-dependent | Stress response |
| p38 MAPK | β-arrestin | Inflammation |
| RhoA | G12/13 coupling | Cytoskeletal dynamics |
NTSR1 signaling is tightly controlled:
NTSR1 exhibits high expression in brain regions associated with motor control and reward:
NTSR1 is centrally involved in PD pathophysiology:
Dopaminergic Modulation: NTSR1 activation modulates dopamine synthesis, release, and receptor signaling. The substantia nigra has particularly high NTSR1 expression, making it a key regulator of dopaminergic neuron function[@bjornstrom2018][@liu2019].
Neuroprotection: NTSR1 agonists have shown neuroprotective effects in multiple models:
NTSR1 contributes to AD through several mechanisms:
Cholinergic Modulation: NTSR1 influences cholinergic neurotransmission, which is prominently affected in AD
Amyloid Interaction: Neurotensin levels are altered in AD brain, potentially affecting amyloid metabolism
Synaptic Dysfunction: NTSR1 signaling modulates synaptic plasticity, which is impaired in AD
Neuroinflammation: NTSR1 in microglia may contribute to neuroinflammatory processes[@kim2020]
NTSR1 has been studied in relation to schizophrenia:
Dopamine Hypothesis Link: Given the close interaction between neurotensin and dopamine systems, NTSR1 may modulate dopamine dysregulation in schizophrenia
Therapeutic Target: NTSR1 antagonists have been explored as potential antipsychotics
Genetic Associations: Some studies link NTSR1 polymorphisms with schizophrenia risk
Beyond the CNS, NTSR1 is implicated in cancer:
NTSR1 signaling promotes dopaminergic neuron survival through multiple mechanisms:
NTSR1 modulates neuroinflammatory responses:
NTSR1 modulates synaptic function in the substantia nigra:
NTSR1 agonists are being developed for PD and other disorders:
| Compound | Stage | Key Features |
|----------|-------|--------------|
| PD-149163 | Research | Brain-penetrant agonist |
| ABS-201 | Preclinical | Selective for NTSR1 |
| SB-612422 | Research | NTSR1/NTSR2 selective |
Agonist benefits in PD:
Antagonists have different therapeutic applications:
Developing NTSR1-targeted therapies faces several challenges:
No current clinical trials for NTSR1 in PD, but preclinical data support advancement: